Press "esc" to clear
Go to Advanced Search

Showing results

110 of 992
Embargo will expire:
16-Nov-2018 11:00 AM EST
Released to reporters:
13-Nov-2018 1:00 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Nov-2018 11:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Embargo will expire:
15-Nov-2018 11:00 AM EST
Released to reporters:
13-Nov-2018 12:05 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 15-Nov-2018 11:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

DaverNaval2.jpg

Article ID: 703788

Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study

University of Texas M. D. Anderson Cancer Center

A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

Released:
13-Nov-2018 10:05 AM EST

Article ID: 703867

Fat fundamentals: Scientists uncover crucial biological circuits that regulate lipids and their role in overall health

McMaster University

Tiny microscopic worms, invisible to the naked eye, are helping scientists to better understand an extraordinarily complex biological pathway that connects fat to overall health and aging in humans.

Released:
13-Nov-2018 7:05 AM EST
  • Embargo expired:
    12-Nov-2018 11:00 AM EST

Article ID: 703505

Hepatitis C Treatment Can Be Shortened in 50 Percent of Patients, Study Finds

Loyola University Health System

Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient. Findings from a new study could lead to big cost savings. In 50 percent of patients, the standard 12-week treatment regimen could be shortened to as little as six weeks without compromising efficacy.

Released:
6-Nov-2018 6:00 PM EST
DaverNaval.jpg
  • Embargo expired:
    8-Nov-2018 9:00 AM EST

Article ID: 703502

Combination chemotherapy and immunotherapy effective in Phase II leukemia study

University of Texas M. D. Anderson Cancer Center

A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.

Released:
7-Nov-2018 9:00 AM EST
  • Embargo expired:
    7-Nov-2018 9:00 AM EST

Article ID: 703490

Call for Nominations: The Endocrine Society’s Award for Excellence in Science and Medical Journalism

Endocrine Society

The Endocrine Society is calling for nominations for the 12th annual Award for Excellence in Science and Medical Journalism. The award recognizes outstanding reporting that enhances public understanding of health issues pertaining to the field of endocrinology.

Released:
7-Nov-2018 9:00 AM EST

Article ID: 703279

High Blood Pressure Poses Risk of Heart/Stroke Events for People Under Age 40

Duke Health

People younger than age 40 who have high blood pressure are at increased risk of heart failure, strokes and blood vessel blockages as they age, according to a study in JAMA led by Duke Health.

Released:
6-Nov-2018 11:00 AM EST

Article ID: 703466

New Checkpoint Inhibitor Shows Promise in Clinical Trial for Non-Hodgkin’s Lymphoma

University of Chicago Medical Center

By combining the experimental anti-cancer antibody known as 5F9 with the anti-cancer antibody rituximab, researchers managing a phase 1b clinical trial were able to induce a positive response in 11 out of 22 people with relapsed/refractory non-Hodgkin’s lymphoma. Eight of the 22 patients went into complete remission from their cancers.

Released:
6-Nov-2018 10:05 AM EST
NickolaiPodoltsevMDPhD.jpg

Article ID: 703425

Yale Cancer Center investigators show recommended, but underused treatment for rare blood cancer saves lives

Yale Cancer Center

U.S. and European guidelines on treating Polycythemia Vera (PV), a potentially deadly blood cancer, call for two treatments for patients with high-risk disease: therapeutic phlebotomy and cytoreductive therapy with a drug called hydroxyurea (HU). HU is the most commonly used option, but evidence for HU treatment is limited and both treatments are underused. Now, researchers at Yale Cancer Center have documented reduced risk of death and incidence of blood clots in patients receiving those therapies.

Released:
5-Nov-2018 5:05 PM EST

Showing results

110 of 992

Chat now!